Did AVITA Medical beat or miss consensus estimates last quarter?

What guidance did AVITA Medical's management provide for the next earnings period?

What factors drove the changes in AVITA Medical's revenue and profit?

What were the key takeaways from AVITA Medical’s earnings call?

What were the key takeaways from AVITA Medical's earnings call?

What is the revenue and EPS growth rate for AVITA Medical year over year?

What is AVITA Medical's gross profit margin?

What does AVITA Medical do and what are its main business segments?

- **Revenue Growth**: 2025 full year revenue $71.6M (+11% YoY), with 2026 guidance of $80-85M driven by utilization normalization and multiproduct adoption.
- **Reimbursement Resolution**: 6/7 MACs published payment rates for RECELL, supporting clinician confidence and utilization.
- **Financial Flexibility**: $18.8M cash post-refinancing; new credit facility removes covenant constraints, enabling execution focus.
- **Multiproduct Momentum**: Early Cohealyx/PermeaDerm adoption in core accounts, with studies nearing completion to support real-world evidence.

**【CEO Summary Section】**
- **Revenue Performance**: Q4 2025 revenue of $17.6 million, full year $71.6 million (+11% YoY). Focus on utilization within 200 core burn/trauma centers, shifting from bulk orders to monthly usage patterns.
- **Reimbursement Clarity**: 6/7 Medicare Administrative Contractors (MACs) have published payment rates for RECELL, reducing clinician uncertainty. Remaining MAC engagement ongoing.
- **Multiproduct Platform**: Cohealyx-1 and PermeaDerm-1 studies nearing completion; early Boswick Symposium cases show combined use of all 3 products, driving higher revenue per patient.
- **2026 Outlook**: $80-85 million revenue target (+12-19% YoY), driven by normalized utilization, expanded portfolio use, and predictable operating environment.

**【CFO Financial Commentary】**
- **Gross Margin**: Full year 82.1% (vs. 85.8% 2024), impacted by product mix (Cohealyx/PermeaDerm contributions) and inventory reserves.
- **Cost Control**: Operating expenses down 9% YoY ($10.4M reduction), driven by lower sales/marketing costs. Q4 cash use improved to $5.1M (from $10.1M Q2).
- **Balance Sheet**: $18.8M cash post-refinancing with Perceptive Advisors. New credit facility removes restrictive covenants, aligning with 2026 growth trajectory.

**【Q&A Highlights】**
- **Revenue Covenant Headroom**: Q1 2026 covenant of $15.4M vs. Q4 2025 revenue of $17.6M; full year guidance comfortably exceeds covenant thresholds.
- **Cohealyx/PermeaDerm Adoption**: VAC reviews progressing; gradual uptake within existing accounts, with no bottlenecks beyond administrative processes.
- **MAC Engagement**: 7th MAC engagement continues; no concerns over eventual rate publication.
- **Execution Focus**: 2026 prioritizes consistent delivery, with Q1 as baseline for progressive growth throughout the year.

AVITA Medical, Inc. (RCEL) Q4 2025 Earnings Call Transcript

- **Revenue Miss and Guidance Adjustment**: Q3 revenue $17.1M (-13% YoY), full-year revised to $70-74M due to reimbursement delays.
- **Reimbursement Resolution**: All MACs resolved provider rates, clearing path for RECELL demand recovery.
- **Commercial Restructuring**: 200 key U.S. accounts targeted for $1.3B opportunity; 24% cost reduction ($23M opex) driving cash flow improvement.
- **Global Expansion**: First European patient treated with RECELL GO; cautious European rollout while focusing on U.S. recovery.
- **Cash Position**: $23.3M cash, $6.2M Q3 cash use (vs. $10.1M Q2), with path to breakeven as revenue recovers.


**【CEO Summary Section】**
- **Q3 2025 Revenue**: $17.1 million, down 13% YoY, due to reimbursement delays and slower-than-expected VAC approvals. Full-year guidance revised to $70-74 million (prior: $76-81 million). 
- **Reimbursement Progress**: All 7 MACs have resolved provider reimbursement rates, clearing uncertainty for RECELL procedures. Early signs of demand recovery as clinicians regain confidence.
- **Market Focus**: 200 key U.S. burn/trauma centers represent $1.3 billion of the $3.5 billion TAM. Current penetration ~5%, with priority on scaling utilization in high-value accounts.
- **Commercial Restructuring**: Streamlined sales org, improved forecasting, and monthly purchasing patterns to drive predictability. 
- **Cost Discipline**: Operating expenses reduced 24% YoY ($23M vs. $30.2M), with $10M annualized savings. Balance sheet flexibility maintained via debt covenant amendments.
- **Global Expansion**: RECELL GO received CE Mark in Europe, with first patient treated in Germany. Limited resources allocated to early-stage European distribution.

**【CFO Financial Commentary】**
- **Gross Margin**: 81.3% (vs. 83.7% Q3 2024), impacted by Cohealyx/PermeaDerm mix (50%/60% ASP share). RECELL gross margin remains stable at 83.6%.
- **Cash Position**: $23.3 million at end of Q3, up from $15.7 million, driven by $13.8 million private placement and reduced cash burn ($6.2M vs. $10.1M Q2). 
- **Debt Management**: Secured Q3 revenue covenant waiver and Q4 amendment to $70 million. Evaluating 2026 capital strategy for cash flow breakeven.

**【Q&A Highlights】**
- **Forecasting**: Improved visibility via rep-level customer engagement and monthly purchasing patterns. 2026 guidance to be updated in Q1 2026.
- **Europe Strategy**: Limited resources for early-stage European launch, with focus on U.S. recovery. No bifurcation of resources expected.
- **VAC Approvals**: ~1/3 of target accounts have Cohealyx VAC submissions; expect ordering to begin post-approval. Synergies from full portfolio utilization in ~20 accounts, but early days.
- **Sales Incentives**: 2026 comp plans to align with growth objectives, emphasizing portfolio sales and utilization consistency.
- **Backlog Catch-Up**: No material impact on 2025 guidance from delayed claims adjudication; focus on 2026 recovery.


AVITA Medical, Inc. (RCEL) Q3 2025 Earnings Call Transcript

- **Revenue Resilience**: Q2 2025 revenue up 21% YoY ($18.4M) despite 20% demand reduction from Medicare claims delays, with Q3 recovery expected.
- **Clinical Breakthrough**: RECELL reduces hospital stay by 36%, validated by U.S. National Burn Registry data, driving $11k+ cost savings per patient.
- **New Revenue Models**: Outcome-based partnerships and NTAP Medicare add-on payments (effective Oct 1) accelerate adoption, adding 150+ monthly units.
- **Portfolio Momentum**: Cohealyx orders surge ($300k+ in July), PermeaDerm sales grow, and mini-RECELL gains traction in trauma centers.
- **Financial Adjustments**: Full-year 2025 revenue guidance revised to $76-81M, with free cash flow and GAAP profitability delayed to 2026.
- **Cost Efficiency**: $10M annual savings from sales force restructuring, supporting cash flow management amid $15.7M balance.


**【CEO Summary Section】**
- **Revenue Growth**: Q2 2025 commercial revenue reached $18.4 million, up 21% YoY, driven by RECELL adoption despite a 20% demand reduction due to Medicare claims processing delays.
- **Reimbursement Headwind**: CMS contractor delays in adjudicating new CPT codes caused provider payment uncertainty, impacting utilization. Resolution is underway, with MACs expected to finalize pricing by Q3 2025.
- **Clinical Impact**: Real-world data from the U.S. National Burn Registry showed RECELL reduces hospital stay by 36% for deep second-degree burns <30% TBSA, leading to $11,000+ cost savings per patient.
- **New Business Models**: Outcome-based partnerships with 2 hospitals offer rebates if length of stay targets aren't met, potentially adding 150+ monthly units. NTAP approval for trauma wounds (effective Oct 1) provides Medicare add-on payments, accelerating adoption.
- **Product Portfolio Momentum**: Cohealyx (collagen matrix) achieved $300k+ orders in July, with 25% of U.S. burn centers submitting VAC approvals. PermeaDerm sales grew, and mini-RECELL for outpatient trauma wounds is gaining traction.
- **Sales Restructuring**: Field headcount reduced from 108 to 82, saving $2.5M/Q2 and $10M annually, supporting cash flow management.

**【CFO Financial Commentary】**
- **Revenue Guidance Update**: Full-year 2025 revenue revised to $76-81 million (prev $100-106M), reflecting first-half headwinds but expecting second-half recovery.
- **Gross Margin**: Q2 gross margin 81.2% (down from 86.1% YoY) due to product mix (lower-margin Cohealyx/PermeaDerm sales) and inventory adjustments.
- **Operating Expenses**: Q2 expenses $26.1 million (-9% YoY), driven by $2M sales & marketing savings and $0.8M G&A reductions. Annualized savings of $10M from restructuring.
- **Cash Position**: $15.7 million as of Q2, with plans to raise additional capital. OrbiMed credit covenant revised to $73-103 million for next 4 quarters, with fee paid in shares.
- **Future Outlook**: Free cash flow expected in Q2 2026, GAAP profitability in Q3 2026 (delayed from prior targets).

**【Q&A Key Highlights】**
- **Claims Resolution Progress**: Multiple MACs have begun adjudicating payments, with steady improvement in July. Resolution expected by Q3, enabling demand rebound.
- **Cohealyx Adoption**: 25% of U.S. burn centers have VAC approvals pending, with early adopters ordering $300k+ in July. Study enrollment for Cohealyx-1 (40 patients) nearing completion.
- **Cash Management**: No waiver of $10M minimum cash balance covenant. ATM remains available with 3.8 million shares outstanding. Restructuring savings offset cash burn pressure.
- **Mini-RECELL Feedback**: Performing well in trauma centers, with shorter graft times (5-10 days vs. 14-28 days) driving interest despite physician behavior change challenges.


AVITA Medical, Inc. (RCEL) Q2 2025 Earnings Call Transcript

- **Market Expansion Success**: US addressable market jumps 7x to $3.5B with multi-product platform. 
- **Strong Q1 Growth**: 67% YoY revenue rise to $18.5M, powered by trauma center expansion. 
- **New Product Impact**: 
  - **Cohealyx**: 7-day graft readiness in trials; full launch with 700cm² sheets. 
  - **RECELL GO mini**: Targets 270K annual trauma cases with <2.5% TBSA wounds. 
- **Cost Efficiency**: $2.5M/Q savings via commercial restructuring; free cash flow expected H2. 
- **Guidance Confidence**: 2025 revenue $100-106M (+55-65% YoY), GAAP profitable by Q4. 
- **Vitiligo Pause**: Temporarily suspending investment due to reimbursement uncertainty.

**【CEO Strategic Overview】**
- **Market Expansion**: Addressable market expanded from $500M to $3.5B in the US, driven by multi-product portfolio (RECELL GO, Cohealyx, PermeaDerm). 
- **Revenue Growth**: Q1 2025 revenue of $18.5M (+67% YoY), with Q2+ growth reaccelerating due to new product launches (RECELL GO mini, Cohealyx). 
- **Product Innovation**: 
  - **RECELL GO mini**: Targets trauma centers with <2.5% TBSA wounds (270K annual cases). Early adoption strong post-Feb launch. 
  - **Cohealyx**: Collagen matrix now fully launched in all sizes, showing 7-day graft readiness in clinical trials. 
  - **PermeaDerm**: Biosynthetic dressing now 60% revenue share (vs. 50% previously). 
- **Commercial Model Shift**: Reduced field headcount from 108 to 82, restructured to focus on selling across 2-stage procedures. Expect $2.5M/Q operating savings. 

**【CFO Financial Highlights】**
- **Revenue**: $18.5M (+67% YoY), driven by RECELL GO adoption and trauma center expansion. 
- **Gross Margin**: 84.7% (down 1.7pts YoY) due to new product mix (50% Cohealyx, 60% PermeaDerm splits). 
- **Expenses**: $27.5M (+3% YoY) but $2.5M/Q savings expected via commercial/operational efficiency. 
- **Cash Flow**: $25.8M cash as of Q1, targeting free cash flow in H2 and GAAP profitability in Q4. 
- **Guidance**: Full year 2025 revenue $100-106M (+55-65% YoY). 

**【Q&A Key Takeaways】**
- **Cohealyx Adoption**: Early Q1 cases showed 7-day graft readiness; full launch with 700cm² sheets on April 1. Expect non-RECELL sales breakout by Q3. 
- **RECELL GO mini Momentum**: Inventory distributed to trauma centers post-Feb launch; aligns with 80%+ of wounds <480cm². 
- **Sales Team Adequacy**: 70-person selling team restructured for 2-stage procedure coverage; no additional hiring needed for 2025 targets. 
- **Vitiligo Pause**: Suspended commercial investment due to reimbursement uncertainty in office-based settings. No future revenue dependence assumed. 
- **Revenue Cadence**: Sequential growth expected Q2-Q4, with Cohealyx VAC approvals driving back-end acceleration.

AVITA Medical, Inc. (RCEL) Q1 2025 Earnings Call Transcript

- **Revenue surge**: Q4 2024 revenue up 30% YoY to $18.4 million, with 2025 guidance of $100-106 million (55%-65% growth).
- **Breakthrough product**: Cohealyx achieves 7-day graft readiness in first human case, cutting hospital stay by 67%.
- **European expansion**: CE Mark for RECELL GO expected mid-2025, adding $1.35 billion TAM in trauma centers.
- **Financial health**: 2025 targets include H2 free cash flow and Q4 GAAP profitability, with $35.9 million cash balance.
- **Product pipeline**: Full commercial launch of Cohealyx (April) and mini-sized RECELL GO (Q1) to dominate trauma wound market.

**【CEO Summary Section】**
- AVITA Medical has transformed into a multiproduct leader in therapeutic acute wound care, expanding from a single product (RECELL) to a portfolio including PermeaDerm, Cohealyx, and RECELL GO Mini.
- Q4 2024 revenue grew 30% YoY to $18.4 million, driven by adoption of RECELL GO in burn centers and new trauma center accounts.
- Full year 2024 revenue reached $64 million, up 29% YoY, with a 2025 guidance of $100-106 million (55%-65% growth).
- Key launches in 2025: Cohealyx (April) and RECELL GO Mini (Q1), targeting 270,000 annual trauma center cases.
- European expansion expected with CE Mark for RECELL GO by mid-2025, adding $1.35 billion TAM in trauma centers.

**【CFO Financial Commentary】**
- Q4 2024 gross margin improved to 87.6%, with full year at 85.8%.
- Operating expenses for Q4 were $26.1 million, stable for 2025 quarters, with no headcount expansion planned.
- 2025 financial targets: free cash flow in H2 and GAAP profitability by Q4.
- Cash balance of $35.9 million as of Q4, with debt covenant amendments providing financial flexibility.

**【Q&A Key Highlights】**
- **Cohealyx adoption**: First human case showed 7-day graft readiness vs. 12-21 days for alternatives, reducing hospital stay from 30 to 10 days.
- **RECELL GO Mini**: 70% trauma center adoption within 1 month, addressing 2.5% TBSA wounds with cost-effective kits.
- **European strategy**: CE Mark progress delayed but expected mid-2025, targeting $1.35 billion TAM in trauma centers.
- **Financial model**: New products (Cohealyx, PermeaDerm) share 50-50 gross margin, lowering overall margin but driving profitability through scale.
- **Debt management**: OrbiMed credit agreement amended to reduce revenue covenant risk, supporting growth without repayment pressure.

Actual	-0.26	-0.26	-0.19	-0.38	-0.25	-0.22	-0.21	-0.37	-0.41	-0.34	-0.28	-0.73	-0.6	-0.62	-0.44	-0.53	-0.38	-0.46	-0.38
Forecast	-0.4879	-0.3501	-0.292	-0.3483	-0.3432	-0.3312	-0.2421	-0.2702	-0.3132	-0.4353	-0.3943	-0.4783	-0.4963	-0.4471	-0.4467	-0.3231	-0.25	-0.3319	-0.3644
Surprise	+46.71%	+25.74%	+34.93%	-9.10%	+27.16%	+33.57%	+13.26%	-36.94%	-30.91%	+21.89%	+28.99%	-52.62%	-20.89%	-38.67%	+1.50%	-64.04%	-52.00%	-38.60%	-4.28%

RCEL

RCEL fundamentals

RCEL Q4 2025 Earnings

Earnings Call

You can ask Aime

RCEL

RCEL fundamentals

RCEL Q4 2025 Earnings

Earnings Call

RCEL Earnings Call Summary for Q4/20254:30 PM on Feb 12, 2026

RCEL Earnings Call Summary for Q3/20254:30 PM on Nov 6, 2025

RCEL Earnings Call Summary for Q2/20254:30 PM on Aug 7, 2025

RCEL Earnings Call Summary for Q1/20253:30 PM on May 8, 2025

RCEL Earnings Call Summary for Q4/20244:30 PM on Feb 13, 2025

You can ask Aime